Advances in Hematology / 2012 / Article / Tab 1 / Review Article
Nonengraftment Haploidentical Cellular Therapy for Hematologic Malignancies Table 1 Summary of nonengraftment cellular therapy results.
Author Number of patients Conditioning regimen Number of CD3 cells infused Response rate (CR/PR) Colvin et al. [16 ] 19 patients (AML/NHL only) 100 cGy TBI 1 × 106 –2 × 108 /kg 37% (26%/11%) Guo et al. [17 ] 30 patients (AML) Mitoxantrone 8–10 mg/m2 (3 days) and cytarabine 150 mg/m2 (7 days) 0.5–2.6 × 108 /kg 80% (80%/NR)
*O’Donnell et al. [18 ] 4 patients (ALL, MDS) Fludarabine 30 mg/m2 , 200 cGy TBI, Post transplant ± Pretransplant cyclophosphamide 2.6–3.8 × 107 /kg 75% (75%/0%)
*Dey et al. [19 ] 22 patients (NHL, HL, Multiple Myeloma) Cyclophosphamide 50 mg/kg (3-4 days), ATG 15–30 mg/kg (3-4 days), and anti-CD 2 monoclonal antibody 1 × 107 –2.98 × 108 /kg 41% (18%/22%)
*Only patients who did not engraft in this study are included in the results. AML= acute myeloid leukemia, NHL= non-Hodgkins lymphoma, MDS= myelodysplastic syndrome, ALL= acute lymphocytic leukemia, HL= Hodgkins lymphoma.